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CAP	 decrease:	 −32	 dB/m	 [−58	 to	 32	 dB/m]).	 In	 parallel,	 serum	ALT	 and	 γ-GT	 ac-
tivities decreased significantly (P = .002 and P	=	.049,	respectively).	These	improve-
ments were accompanied by significant (P	<	.0001)	changes	to	body	weight	and	BMI	
(−2.5	±	3.3	 kg	 and	−0.9	±	1.2	 kg/m2,	 respectively)	 and	 glucose	homeostasis,	with	
significant	reductions	in	HbA1c and fasting plasma glucose (FDG) (both P < .0001). Of 
note,	significant	reductions	of	intrahepatic	lipid	contents	occured	in	patients	receiv-
ing	SGLT-2	inhibitors	only.
Conclusions: In	 this	 real-world	 observational	 evaluation	 of	 fatty	 liver	 monitored	
noninvasively	in	patients	with	type	2	diabetes	treated	with	either	SGLT2	or	GLP-1,	 
improvements	in	measures	of	hepatic	steatosis,	glucose	and	weight	parameters	were	
observed	after	6	months,	with	significant	 reductions	of	 intrahepatic	 lipid	contents	
seen	specifically	in	the	SGLT2	subgroup.
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betes	play	a	prominent	role	in	NAFLD	risk.1 The global prevalence of 
NAFLD	is	currently	estimated	at	almost	25%2 and is diagnosed in up 




being	 investigated	 for	 possible	 liver-related	 benefits.	 The	 PIVENS	
trial	 observed	 the	 insulin-sensitizing	 drug	 pioglitazone	 to	 improve	
liver	histopathology	and	liver	enzymes4;	however,	it	was	associated	






in	 the	 setting	 of	 diabetes	 and	NAFLD.9-14	Glucagon-like	 peptide-1	
(GLP-1)	analogues	induce	weight	loss	and	insulin	sensitivity	and,	like	
SGLT2	inhibitors,	improve	liver	histopathology	and	serum	surrogate	
markers	in	mouse	NASH	models.15-18 Reductions in hepatic fat con-
tents	and	in	LFTs	have	been	demonstrated	in	some19,20 but not all21 
studies	in	patients	with	diabetes	and	NAFLD.









II	 (Gastroenterology	 and	 Endocrinology),	 at	 Saarland	 University	
Medical	Center.	Women	and	men	over	18	years	of	age	were	included	
if the following criteria were fulfilled: ability to provide informed 
consent;	type	2	diabetes	with	or	without	current	anti-diabetic	medi-
cation;	HbA1c	≥	6.5%	(48	mmol/mol);	presence	of	hepatic	steatosis	
by	 controlled	 attenuation	 parameter	 (CAP	 value	 ≥215	 dB/m	using	
transient elastography)22; and were about to begin therapy with 
SGLT-2	 inhibitors	or	GLP-1	analogues.	The	choice	of	specific	drugs	
was made by physicians board licensed for internal medicine and/
or	 endocrinology,	 who	 supervised	 the	 treatment	 of	 the	 individual	








Exclusion	 criteria	 included	 the	 following:	 liver	 cirrhosis	 (liver	
stiffness	measurement	 during	 elastography	≥13	 kPa);	 viral	 hepati-
tis	or	drug-induced	hepatopathy;	alcohol	consumption	≥21	drinks/
wk	 (30	 g	 alcohol/d)	 in	men	 and	 ≥14	 drinks/wk	 (20	 g	 alcohol/d)	 in	
women,	as	assessed	using	the	Alcohol	Use	Disorders	Identification	
Test questionnaire23; noncompliance with medical therapy; glomer-








criteria,	 and	 upon	 initiation	 of	 GLP-1	 analogues	 or	 SGLT-2	 inhibi-
tors,	patients	were	followed	up	after	4	weeks	and	3	and	6	months.	
Changes	to	existing	medications	during	the	study	were	documented	
as was compliance with the aforementioned prescribed medica-
tions	using	the	pill-count	(or	equivalent)	method.	As	summarized	in	
Figure	1,	the	following	data	were	obtained	during	each	visit:
2.2.1 | Serum biochemistry and clinical assessments
Blood	was	 collected	 for	 biochemical	 analyses:	 liver	 function	 tests	
(LFTs)	 including	 serum	 aminotransferase	 activities	 (alanine	 ami-




cholesterol	 (TC),	 low-density	 lipoprotein	 (LDL)	 cholesterol,	 high-
density	 lipoprotein	 (HDL)	 cholesterol	 and	 serum	 triglyceride	 (TG)	
F I G U R E  1   Description of the study 
design including the assessments carried 
out	during	this	real-world	observational	
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Assessments at each time point:




Liver function tests, markers of 
glucose & lipid metabolism
Start therapy with 
GLP-1 analogues or 
SGLT-2 inhibitors
Follow-ups








Vibration-controlled	 transient	 elastography	 (VCTE)	 (FibroScan®,	
Echosens,	 Paris)	 with	 controlled	 attenuation	 parameter	 (CAP)	
quantified	 hepatic	 fat	 contents,	 and	 concurrent	 liver	 stiffness	
measurements	 (LSM)	were	 documented.	 This	 technique	 has	 been	
recommended by the joint clinical practice European guidelines.25 
VTCE	with	CAP	was	repeated	10	times	to	obtain	the	final	value,	and	
values	≥215	dB/m	determined	the	presence	of	hepatic	steatosis.26 
As	 recommended	 previously,	 liver	 stiffness	 measurement	 (LSM)	
results	were	included	in	the	analysis	if	the	success	rate	was	≥	60%	
based on at least 10 valid measurements and the interquartile range 
(IQR)/median	LSM	≤	30%,27	unless	the	LSM	<	7.1	kPa,	in	which	case	
the	IQR/LSM	ratio	was	not	considered.28
2.2.3 | Anthropometry including body composition
The	 stadiometer	 seca217	 (seca)	 was	 used	 to	 measure	 height	 and	
a	 measuring	 tape	 for	 waist	 circumference.	 The	 eight-electrode	
segmental	 multifrequency	 Medical	 Body	 Composition	 Analyzer	
mBCA515	(Seca	GmbH)	quantified	body	composition	through	bio-
electrical	 impedance	analysis	 (BIA).	This	BIA	instrument	can	meas-
ure	 fat	 mass	 (FM),	 fat-free	 mass	 (FFM),	 total	 body	 water	 (TBW),	
phase	angle	(PA)	and	visceral	fat	(VF)	using	frequencies	of	5	kHz	and	
50	kHz	and	empirical	linear	regression	models.	Impedance	is	deter-
mined through body resistance (R) and reactance (Xc) to a flow of 
alternating	 electrical	 current.	MetS	was	 diagnosed	when	 three	 of	
the	following	five	conditions	were	present:	abdominal	adiposity,	ele-
vated	serum	triglycerides,	decreased	HDL	cholesterol,	hypertension	
and elevated fasting glucose.29
2.3 | Study outcomes and statistics
Changes	 in	 hepatic	 steatosis	 using	 CAP	 after	 4	weeks	 and	 3	 and	
6	months	of	medical	management	with	GLP-1	analogues	or	SGLT-2	
inhibitors formed the primary outcome. Secondary outcomes in-
cluded	changes	to	body	composition,	LFTs,	lipid	status	and	glucose	
metabolism	 markers	 as	 well	 as	 to	 LSM.	 Subgroup	 analysis	 ex-
plored	the	specific	effects	of	the	two	types	of	medications	(GLP-1	
analogues	 and	 SGLT-2	 inhibitors).	 The	 Kolmogorov-Smirnov	 and	
Shapiro-Wilk	 tests	were	 used	 to	 test	 for	 normality	 of	 data	 distri-
butions,	 and	 depending	 on	 the	 outcome,	 either	 mean	 ±	 standard	
deviation or median (interquartile range) was used to report results 
and to guide the appropriate statistical tests. Paired Student's t test 
and	Wilcoxon	 signed	 rank	 test	 assessed	differences	between	 two	
dependent	samples,	and	t	test	or	Mann-Whitney	U test evaluated in-
dependent	samples.	Repeated	measures	ANOVA	and	the	Friedman	
test assessed for changes over time for related samples. Data for the 
subgroup	analyses	are	represented	by	median	(interquartile	range),	















indicates severe histological steatosis grade (S3).22
Liver	 stiffness	 measurements	 ranged	 from	 absent	 to	 minimal	
liver	fibrosis	for	most	patients	(7.2	kPa,	5.3-8.4	kPa).	Serum	amino-
transferase	 activities	 as	 surrogate	markers	 of	 liver	 injury	were	 el-
evated	in	12	patients	only	(31%;	n	=	3	for	AST;	n	=	9	for	ALT)	and	
γ-GT	 levels	 in	 12	 (31%)	 patients.	 Additionally,	 three	 patients	 (8%)	
presented	with	raised	AP	activities.
All	 patients	 apart	 from	 one	were	 either	 overweight	 (n	 =	 7)	 or	
obese	 (n	=	31),	and	35	patients	had	visceral	adiposity	as	 reflected	
by	 elevated	WC	measurements,	 based	 on	 the	 standard	 European	
cut-offs	of	94	cm	for	men	and	80	cm	for	women.30 In terms of bio-
chemical	metabolic	parameters,	the	HOMA-IR	score	was	elevated	in	
36	patients.	Lipid	status	was	assessed	using	TC,	which	was	elevated	




All	 patients	 except	 for	 one	were	 diagnosed	with	MetS,	 as	 de-
fined	by	Alberti	et	al.29 The concomitant medications were as fol-
lows:	fourteen	patients	were	taking	insulin	only,	30	metformin,	ten	




spectively. The regimens for these mediations remained unchanged 
throughout the duration of the study.
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3.2 | Changes of hepatic phenotypes
Figure 2 illustrates a significant (P	 =	 .026)	 reduction	 of	 CAP	 in	
the	entire	cohort	during	the	6-month	observation	period,	 includ-
ing	 individual	 CAP	 reductions	 for	 each	 point	 in	 time.	 This	 over-
all	CAP	 reduction	 corresponds	 to	 a	median	 relative	 reduction	of	
8.9%.	 Table	 1	 shows	 the	 values	 for	 each	 time	 point	 (4	weeks,	 3	
and	6	months)	as	well	as	the	overall	absolute	and	relative	changes	
for	 all	 liver-related	 parameters.	 Furthermore,	 when	 comparing	
CAP	at	specific	 time	points,	both	the	values	at	4	weeks	 (T1)	and	




surrogate	markers,	 significant	 reductions	were	observed	 for	ALT	
(P = .002) and γ-GT	(P	=	.049).
TA B L E  1  Baseline	and	follow-up	data	for	the	entire	cohort
 
Baseline 
(n = 39) 4 wk (n = 39) 3 mo (n = 39) 6 mo (n = 36) P Change Relative change
Sex	(M/F) 20/19       
Age	(y) 57.7	±	10.9       
Transient elastography
CAP	(dB/m) 338	(311-363) 313	(296-341) 316	(284-341) 337	(280-360) .026 −32	(−58	to	32) −8.9	(−16.9	to	10.0)
LSM	(kPa) 6.9	(5.3-8.4) 6.4	(5.4-7.6) 6.8	(5.7-7.9) 6.1	(5.4-8.1) .857 −0.5	(−2.6	to	0.9) −7.7	(−31.5	to	17.6)
Anthropometry/body	composition
Weight	(kg) 100.8	±	17.7 99.0	±	18.2 98.7	±	19.0 97.5	±	18.3 .000 −2.5	±	3.3 −2.8	±	3.4
BMI	(kg/m2) 34.3	±	4.9 33.7	±	5.0 33.5	±	5.3 33.3	±	5.3 .000 −0.9	±	1.2 −2.7	±	3.6
Fat-free	mass	(kg) 60.2	±	11.9 59.3	±	11.9 59.4	±	12.0 58.3	±	12.0 .013 −1.1	±	1.9 −1.9	±	3.2
Fat	mass	(kg) 40.6	±	11.7 39.7	±	11.8 39.3	±	12.0 38.7	±	12.1 .027 −1.4	±	3.1 −4.0	±	7.7
Total	body	water	(L) 45.0	±	8.0 44.3	±	8.4 44.0	±	9.0 43.5	±	8.4 .005 −0.9	±	1.5 −2.1	±	3.3
Visceral	fat	(L) 4.6	(3.2-6.9) 4.7	(3.5-6.3) 4.3	(3.2-6.1) 4.0	(3.0-6.0) .056 −0.6	±	0.8 −9.5	±	17.1
WC (cm) 116	±	13 114	±	12 113	±	14 113	±	13 .073 −0.3	±	0.5 −2.8	±	4.5
Phase angle 5.1	(4.6-5.6) 5.3	(4.8-5.5) 5.2	(4.6-5.7) 5.2	(4.9-5.7) .105 −0.3	±	0.3 −0.5	±	5.2
Biochemistry
Liver	function	tests        
AST	(U/L) 24	(18-32) 25	(20-34) 22	(18-28) 24	(20-28) .059 −2	(−6	to	2) −7.4	(−22.2	to	8.3)
ALT	(U/L) 28	(22-43) 29	(22-44) 25	(20-32) 29	(20-41) .002 −2	(−14	to	2) −12.5	(−30.2	to	7.4)
γ-GT	(U/L) 36	(24-54) 31	(24-49) 31	(23-47) 33	(24-49) .049 −4	(−15	to	1) −11.1	(−28.9	to	4.4)
AP	(U/L) 79	(63-87) 74	(58-89) 73	(62-95) 73	(60-95) .623 −1	(−7	to	3) −1.2	(−8.8	to	4.8)
Glucose-related	
parameters
       
HbA1c	(%) 8.0	(7.2-9.0) N/A 7.3	(7.0-7.7) 7.4	(6.7-7.8) .000 −0.6	(−1.4	to	−0.4) −7.1	(−17.5	to	−4.9)
FPG	(mg/dL) 184	(140-212) 142	(135-174) 143	(130-160) 135	(126-151) .000 −35.5	(−69.0	to	−7.0) −21.6	(−33.3	to	−6.3)
Insulin (mIU/ml) 12.3	(10.7-22.6) 9.7	(7.2-19.2) 12.5	(8.5-22.1) 12.2	(7.1-17.9) .138 −2.1	(−6.3	to	2.3) −14.7	(−49.2	to	20.9)
C-Peptide	(ng/mL) 2.7	(1.8-3.3) 2.3	(1.5-2.9) 2.7	(2.2-3.7) 2.3	(1.4-3.0) .050 −0.1	(−0.7	to	0.5) −6.5	(−33.3	to	16.2)
HOMA-IR	score	
(FPGXIns/405)
5.9	(3.8-10.6) 4.1	(2.4-6.7) 4.6	(2.8-8.1) 4.1	(2.2-7.2) .029 −1.8	(−4.9	to	−0.2) −36.8	(−60.2	to	5.0)
Lipid	status        
TG	(mg/dL) 153	(118-259) 159	(124-217) 142	(106-192) 155	(106-195) .464 −26	(−58	to	8) −14.5	(−30.6	to	8.0)
TC	(mg/dL) 181	±	42 176	±	40 179	±	41 180.3	±	46.2 .857 −1.2	±	27.1 −0.3	±	14.4
LDL-C	(mg/dL) 106	±	28 104	±	30 111	±	33 108.3	±	36.9 .699 3.2	±	25.4 3.5	±	25.2
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3.3 | Changes to body composition and other 
metabolic markers
Table	 1	 summarizes	 the	 baseline	 and	 follow-up	 values,	 in	 addition	
to the change score for the parameters related to body composition 
and	metabolic	markers.	Specifically,	a	significant	reduction	of	weight	
(2.5	±	3.3	kg)	and	BMI	 (−0.9	±	1.2	kg/m2)	occured	during	 follow-up	
(both P	<	 .0001).	BIA	analysis	 revealed	 the	weight	 reductions	 to	 re-
sult	 from	significant	decreases	 in	FFM	(P	=	 .013),	FM	(P	=	 .027)	and	
TBW	(P	=	.005),	with	the	following	mean	relative	reductions	observed:	
−1.9	±	3.2	kg,	−4.0	±	7.7	kg,	and	−2.1	±	3.3	L,	 respectively.	WC	de-
creased	marginally	 in	 the	 follow-up	period	 (−0.3	±	0.5	 cm,	P	 >	 .05).	
Marked	improvements	of	glucose-related	parameters	occurred	during	
the	6-month	period,	with	significant	reductions	in	HbA1c and fasting 





3.4 | Association of SGLT-2 inhibitors and GLP-1 
analogues with liver-related effects
Table	 2	 presents	 the	 values	 at	 baseline	 and	 after	 6	months	 for	 all	
parameters	 based	 on	 the	 type	 of	medication	 (SGLT-2	 inhibitors	 or	
GLP-1	 analogues).	 No	 differences	 between	 patient	 characteristics	
were demonstrated at baseline between the two groups. Stratified 
analysis revealed significant (P	=	.014)	reductions	in	CAP	to	occur	in	
patients	receiving	SGLT-2	inhibitors	but	not	for	those	receiving	GLP-1	
analogues (P	=	 .562).	Here,	patients	 taking	SGLT-2	 inhibitors	had	a	
median	absolute	CAP	reduction	of	38	dB/m	(−58	to	9	dB/m),	which	
corresponded	to	a	11.3%	reduction	(−17.1%	to	2.7%).	Further	analysis	
revealed significant differences to occur at T1 and T2 as compared 
to	baseline	CAP	(P = .009 and P	=	.035,	respectively).	Figure	3	shows	
the	baseline	and	follow-up	CAP	values	for	each	of	the	two	groups,	in	
addition to the corresponding individual patient data.




decreased	 significantly	 by	 2	 U/L	 (−9	 to	 0	 U/L)	 in	 those	 receiving	
GLP-1	analogues	(P = .029).
3.5 | Association of SGLT-2 inhibitors and GLP-1 
analogues with changes of body composition and 
metabolic markers
Body	weight	(but	not	BMI)	decreased	significantly	(P	=	.006)	in	the	
SGLT-2	 group	 (mean	 reduction	 2.3	 ±	 3.8	 kg).	 Both	 body	 weight	
and	 BMI	 decreased	 significantly	 (P	 <	 .0001)	 by	 2.8	 ±	 2.5	 kg	 and	




HbA1c were significantly (P	<	 .0001)	 reduced	 in	 the	SGLT-2	group.	
These	values	decreased	by	31	mg/dL	 (−62	 to	−7	mg/dL)	and	0.5%	
(−1.9%	to	−0.4%),	respectively.	Greater	reductions	of	FPG	and	HbA1c 




3.6 | Hepatic response associated with SGLT-2 





hepatic	 response	 to	differ	 from	 those	without	with	 respect	 to	BMI,	
which was lower in the responders (P	=	.049).	Moreover,	baseline	CAP	
values	were	markedly	higher:	360	 (338-372)	dB/m	vs	315	 (281-331)	
dB/m	(P = .002). This illustrates that the response occured in patients 
with more severe hepatic steatosis (see Table 3). These patients pre-
sented	with	lower	baseline	LSM	(P	=	.008)	as	well	as	lower	AST	and	ALT	
activities (P = .029 and P	=	.026,	respectively).
As	summarized	in	Table	4,	a	post	hoc	univariate	linear	regression	
analysis	found	baseline	CAP	and	BMI	to	be	significant	determinants	
of	absolute	CAP	change	 (P = .003 and P	=	 .012,	 respectively),	but	




ti-diabetics	(P = .001 and P	=	.002,	respectively).
F I G U R E  2  Change	in	CAP	values	during	the	observation	period	









































When	 conducting	 stratified	 analysis,	 the	 beneficial	 effects	 on	
liver	 fat	 appeared	 to	 primarily	 occur	 in	 patients	 receiving	 SGLT-2	
inhibitors. These findings support other studies in patients re-
ceiving	 SGLT-2	 inhibitors.9,10,12,14,32-35	 An	 open-label	 trial	 in	 Japan	





PBaseline (n = 22) 6 mo (n = 21) Baseline (n = 17) 6 mo (n = 15)
Sex	(M/F) 12/10  8/9  
Age	(y) 56	(50-62)  66	(56-68)  
Transient elastography
CAP	(dB/m) 338	(311-371) 336	(274-353) .014 341	(316-360) 337	(295-368) .562
LSM	(kPa) 6.4	(5.3-7.4) 6.1	(5.6-8.1) .438 7.4	(6.7-1.5) 6.1	(5.0-7.8) .568
Anthropometry/body	composition
Weight	(kg) 95.6	(89.3-108.2) 94.0	(85.9-107.8) .006 101.7	(91.0-116.5) 96.8	(87.1-114.0) .000
BMI	(kg/m2) 33.2	(29.6-37.0) 32.1	(29.3-36.7) .069 34.8	(33.0-38.7) 33.1	(31.2-39.0) .000
Fat-free	mass	(kg) 63.3	(48.8-65.9) 6.8	(49.5-65.8) .052 61.5	(48.8-72.2) 59.2	(48.4-67.4) .296
Fat	mass	(kg) 38.7	(28.8-48.2) 37.8	(26.7-44.9) .108 41.0	(34.0-51.2) 36.5	(3.1-5.0) .107
Total	body	water	(L) 46.4	(36.7-49.1) 44.3	(37.4-48.5) .016 46.3	(38.3-53.7) 44.3	(36.5-49.8) .300
Visceral	fat	(L) 4.1	(3.2-6.9) 4.0	(3.3-5.4) .305 5.2	(3.8-7.4) 4.5	(3.9-5.5) .211
WC (cm) 111	(106-121) 112	(104-117) .427 120	(112-129) 118	(114-120) .160
Phase angle 5.3	(5.0-5.6) 5.2	(4.9-5.5) .093 4.8	(4.5-5.3) 5.0	(4.8-5.7) .414
Biochemistry
Liver	function	tests
AST	(U/L) 25	(18-35) 25	(17-32) .045 21	(19-28) 21	(20-25) .508
ALT	(U/L) 32	(25-52) 29	(23-43) .052 26	(21-30) 25	(18-35) .029
γ-GT	(U/L) 48	(28-71) 34	(24-49) .385 33	(24-51) 32	(25-39) .082
AP	(U/L) 80	(66-87) 70	(58.5-87.5) .264 75	(61-106) 74	(65-121) .714
Glucose-related	parameters
HbA1c	(%) 8.4	(7.2-9.2) 7.6	(7.1-8.0) .000 7.6	(7.2-8.8) 7.2	(6.7-7.6) .006
FPG	(mg/dL) 160	(139-221) 143	(129-165) .001 186	(146-198) 129	(117-137) .006
Insulin	(mIU/mL) 11.6	(10.7-16.1) 1.9	(4.6-15.4) .188 17.1	(1.9-25.7) 14.8	(9.7-31.0) .720
C-Peptide	(ng/mL) 2.6	(1.9-3.1) 2.3	(1.5-2.8) .075 2.8	(1.8-3.3) 2.2	(1.4-3.0) .470
HOMA-IR	score	
(FPGXIns/405)
4.9	(3.8-8.9) 4.0	(1.5-4.8) .026 8.0	(5.0-12.3) 4.7	(2.7-1.4) .277
Lipid	status
TG	(mg/dL) 165	(123-259) 163	(121-197) .104 153	(92-255) 121	(93-179) .580
TC	(mg/dL) 182	(166-205) 165	(123-259) .463 171	(141-192) 163	(127-177) .101
LDL-C	(mg/dL) 105	(86-122) 112	(87-147) .105 102	(87-122) 98	(63-114) .055

















pathological benefit in nine Japanese cases with diabetes mellitus and 
NAFLD	who	received	canagliflozin	100	mg	once/daily	for	24	weeks.10 




reduction	 when	 taking	 SGLT-2	 inhibitors	 vs	 placebo,	 in	 the	 secre-
tion	of	 the	transmembrane	hepatic	protein,	soluble	dipeptidyl	pep-
tidase-4,	which	triggers	both	inflammation	and	insulin	resistance.39
TA B L E  2   (Continued)
























































































WC (cm) 114	(105-123) 122	(112-134)
Phase angle 5.1	(4.6-6.7) 6.2	(4.6-5.6)




































8 of 10  |     MITTAG-ROUSSOU eT Al.
In	our	study,	patients	receiving	GLP-1	analogues	displayed	non-
significant	decreases	of	CAP	after	6	months.	This	is	consistent	with	
other studies reporting no significant benefits to hepatic steatosis 
for	GLP-1	analogues.20,21	For	example,	the	12-week	randomized	pla-
cebo-controlled	Dutch	trial	administering	1.8	mg	liraglutide/d	in	17	
overweight patients with diabetes did not observe liver fat reduc-
tion,	as	assessed	by	proton	magnetic	resonance	spectroscopy	 (1H-








and type 2 diabetes.40 Five patients also received transient elas-




been	 reported	 for	GLP-1	analogues.19,41	For	 instance,	 the	phase	 II	
multicentre	 LEAN	 trial	 conducted	 in	 the	 UK	 demonstrated	 his-
topathological	 resolution	 of	 NASH	 in	 nine	 of	 23	 normal-weight	
patients	 receiving	1.8	mg	 liraglutide/d	 for	48	weeks	 vs	 two	of	22	
patients on placebo.19	Moreover,	body	weight	 improved	and	there	
was	 less	worsening	 of	 fibrosis.	Of	 note,	 the	 presence	 of	 diabetes	
did	not	influence	these	findings.	In	addition,	the	single-centre	Lira-
NAFLD	study	conducted	in	France,	which	availed	of	1H-MRS	in	68	
patients	 with	 NAFLD	 and	 uncontrolled	 type	 2	 diabetes	 (defined	
by	HbA1c	 >	 7%/53	mmol/mol),	 reported	 a	 significant	 reduction	of	







are	 potential	 confounders,	 were	 not	 documented	 systematically	
during	the	study.	Of	note,	however,	no	serious	adverse	events	were	





noninvasively in patients with type 2 diabetes treated with either 
SGLT2	or	GLP-1,	we	observed	 improvements	 in	measures	of	he-
patic	 steatosis,	 glucose	 and	 weight	 parameters	 after	 6	 months,	
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